文献速递肝病

碱性磷酸酶正常化对原发性胆汁性胆管炎无并发症生存的影响

Impact of Alkaline Phosphatase Normalization on Complication-Free Survival in Primary Biliary Cholangitis.
PubMed 文献 · Am J Gastroenterol · 2026-03-02

本研究在真实世界原发性胆汁性胆管炎(PBC)队列中比较了熊去氧胆酸(UDCA)单药治疗下碱性磷酸酶(ALP)正常化与仅达 adequate 反应(ALP > ULN 且 < 1.5×ULN)患者的无并发症生存。结果显示ALP正常化、总胆红素(TB)≤0.6×ULN或两者均达标均显著改善无事件生存并降低严重临床事件风险,高危患者获益最大。

要点

  • UDCA治疗下ALP正常化较仅ALP<1.5×ULN显著延长无事件生存并降低事件风险。
  • TB≤0.6×ULN及ALP正常化联合达标者获益更大,高危患者获益最显著。
  • 生化阈值(ALP正常化、TB≤0.6×ULN)可作为PBC治疗目标。

核心结论

  • UDCA治疗下实现ALP正常化和/或TB≤0.6×ULN与PBC患者无并发症生存显著改善相关,尤其在高危患者中。

研究设计与样本

  • 真实世界队列研究,比较UDCA单药治疗下ALP正常化(≤ULN)与仅达adequate反应(ALP>ULN且<1.5×ULN)患者的无并发症生存。

主要发现

  • ALP正常化者无事件生存延长1.34年(95%CI 0.56–2.11;P=0.001)。
  • TB≤0.6×ULN者无事件生存延长3.7年(95%CI 3.11–4.29;P<0.001)。
  • 两者均达标者无事件生存延长4.51年(95%CI 4.13–4.88;P<0.001)。
  • ALP正常化者严重临床事件风险降低(HR 0.34;95%CI 0.15–0.80;P=0.01)。
  • TB≤0.6×ULN者风险降低(HR 0.23;95%CI 0.09–0.55;P=0.001),两者均达标者HR 0.14(95%CI 0.05–0.38;P<0.001)。

关键数值与推荐

  • ALP正常化定义为ALP≤ULN;adequate反应定义为ALP>ULN且<1.5×ULN。
  • TB阈值定义为≤0.6×ULN。
  • 高危患者定义为肝硬度≥10 kPa或临床、组织学或实验室证据提示肝硬化或门脉高压。

临床怎么用

  • 在PBC管理中应将ALP正常化和TB≤0.6×ULN作为有意义的治疗目标,尤其对高危患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Despite the widespread use of ursodeoxycholic acid (UDCA) in primary biliary cholangitis (PBC), many patients remain at risk of progression. Emerging data suggest that normalization of alkaline phosphatase (ALP) and total bilirubin (TB)-particularly when TB < 0.6 times the upper limit of normal (× ULN)-is associated with improved outcomes compared with ALP reduction to < 1.5 × ULN. This study investigated the association between ALP normalization in response to UDCA and long-term clinical outcomes in a real-world cohort of patients with PBC. METHODS: We compared complication-free survival in patients achieving an ALP > ULN and < 1.5 × ULN (adequate response) with those with an ALP ≤ ULN on UDCA monotherapy. Complication-free survival was defined as the absence of serious liver-related clinical events. Restricted mean survival time was used to quantify survival time gained. RESULTS: Patients achieving normal ALP and/or TB ≤ 0.6 × ULN demonstrated significantly improved complication-free survival compared with those with an adequate ALP response. Event-free survival was extended by 1.34 years (95% CI: 0.56, 2.11; P = 0.001) for ALP normalization alone, 3.7 years (95% CI: 3.11, 4.29; P < 0.001) for TB ≤ 0.6 × ULN, and 4.51 years (95% CI: 4.13, 4.88; P < 0.001) for those meeting both criteria. The risk of severe clinical events was reduced in patients achieving ALP normalization (hazard ratio [HR] 0.34; 95% CI: 0.15, 0.80; P = 0.01), TB ≤ 0.6 × ULN (HR 0.23; 95% CI: 0.09, 0.55; P = 0.001), or both (HR 0.14; 95% CI: 0.05, 0.38; P < 0.001). High-risk patients, defined by liver stiffness measurement ≥ 10 kPa or clinical, histological, or laboratory evidence of cirrhosis or portal hypertension, derived the greatest benefit. DISCUSSION: Achieving normal ALP and TB ≤ 0.6 × ULN is associated with significantly improved complication-free survival, particularly in high-risk patients. These findings highlight the potential of biochemical thresholds as a meaningful therapeutic goal in PBC management.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Reddy A, Martins A, Bowlus CL, et al. Impact of Alkaline Phosphatase Normalization on Complication-Free Survival in Primary Biliary Cholangitis. Am J Gastroenterol. 2026. PMID: 41769906. doi:10.14309/ajg.0000000000003973

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。